UWCCC Molecular Tumor Board Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Wisconsin, Madison
About this trial
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Eligibility criteria
Qualifiers
Clinically suspected or histologically confirmed solid or hematological malignancy
Undergoing genetic testing of tumor
Ability to understand written informed consent document
Willingness to sign written informed consent document
Disqualifiers
Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
Trial design
Treatments tested in this trial
- PMMTB (Precision Medicine Molecular Tumor Board)
Treatment groups
10,000 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Wisconsin, Madison
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov